K.M. Shermock

Johns Hopkins Hospital — United States

Economics, Econometrics and Finance · Social Sciences

2h-index25citations12works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(4), Venous Thromboembolism Diagnosis and Management(3), Pharmaceutical Practices and Patient Outcomes(2), Prostate Cancer Treatment and Research(2), Diabetes Management and Education(2)

Publications12 total

Comparative performance of khorana, padua, and improve-VTE risk assessment models for venous thromboembolism risk stratification in hospitalized oncology patients
Blood·2025Open Access
Cost of Care for Gastric Cancer In Patients With and Without Metastases
Value in Health·2015
Effect of A Pharmacy-Based Diabetes Management Program on Glycemic Control in an Inpatient General Medicine Population
Value in Health·2014
Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases
Applied Health Economics and Health Policy·2014· 17 citedOpen Access
Adherence Rates for Intravenous Chemotherapy Regimens to Treat Colon Cancer
Value in Health·2013· 3 citedOpen Access
Impact of a pharmacy-based diabetes management program on glycemic control in an inpatient general medicine population
Value in Health·2013Open Access
Hidden barriers to delivery of pharmacologic venous thromboembolism prophylaxis: The role of nursing beliefs and practices
Value in Health·2013· 1 cited
Health care costs in patients with bone metastasis secondary to prostate cancer compared to prostate cancer patients without bone metastasis in the optum oncology research database
Value in Health·2013
Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies
Value in Health·2013· 1 citedOpen Access
PCV68 FACTORS ASSOCIATED WITH NON-ADMINISTRATION OF ORDERED PHARMACOLOGIC VENOUS THROMBOEMBOLISM PROPHYLAXIS DOSES
Value in Health·2011
PMD36 FAILURE OF INTERNATIONAL ORGANIZATION FOR STANDARDIZATION GUIDELINES TO REPORT CLINICALLY RELEVANT INFORMATION ABOUT POINT-OF-CARE INR DEVICE PERFORMANCE
Value in Health·2011· 1 citedOpen Access
Outcomes Research in the Health-Care System: Driven by Results
Value in Health·2002· 2 citedOpen Access

Frequent Co-authors

Michael B. Streiff(5), Leigh Efird(5), Brian Seal(4), Carl V. Asche(4), Elliott R. Haut(4), Peggy S. Kraus(4), S. Elder(3), Erin Zagadailov(2), Michael Eaddy(2), Deborah B. Hobson(2), Cynthia S. Rand(2), Brandyn Lau(2), Brian Pinto(2), D.M. Lavallee(2), Sean D. Sullivan(1), Scott D. Ramsey(1), Syam Sarma(1), Eileen Farrelly(1), Sibyl Anderson(1), J. Cameron(1)